Supplementary Data — Inhaled Heparin reduces COVID-19 risk: real-time meta analysis of 3 studies

@CovidAnalysis, November 2025, Version 1V1
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DeNucci (DB RCT) 42% 0.58 [0.24-1.44] death 6/38 10/37 Improvement, RR [CI] Treatment Control DeNucci (DB RCT) 42% 0.58 [0.24-1.44] ventilation 6/38 10/37 DeNucci (DB RCT) 5% 0.95 [0.66-1.37] hosp. time 38 (n) 38 (n) Smith (RCT) -70% 1.70 [0.16-17.6] death 2/27 1/23 Intubated patients Smith (RCT) 15% 0.85 [0.06-12.9] death 1/27 1/23 Intubated patients INHALE-HEP van Haren (RCT) 58% 0.42 [0.21-0.80] death 12/182 29/186 INHALE-HEP van Haren (RCT) 71% 0.29 [0.15-0.58] death 10/235 34/238 INHALE-HEP van Haren (RCT) 47% 0.53 [0.31-0.86] ventilation 21/234 40/235 INHALE-HEP van Haren (RCT) 23% 0.77 [0.61-0.95] hosp. 238 (n) 240 (n) Inhaled heparin COVID-19 outcomes c19early.org November 2025 Favors inhaled heparin Favors control
Fig. S1. All outcomes.